Concepedia
Statistics
Publications
6
Citations
207
H-Index
Active since
2009
Affiliations
Chinese University of Hong Kong(Current)
University of Hong Kong
University of Pittsburgh
Prince of Wales Hospital
Cecilia P. Y. Lau is an author at Chinese University of Hong Kong specializing in medicine, oncology, and cancer pharmacology.
Publications per year
2009–2013
The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
Vivian Wai Yan Lui, Edwin P. Hui, Cecilia P. Y. Lau et al. · Investigational New Drugs · 2009 · 60 citations
Medicine, Oncology, Pharmacology +16
Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines
Vivian Wai Yan Lui, Connie W. C. Hui, Cecilia P. Y. Lau et al. · Investigational New Drugs · 2012 · 43 citations
Medicine, Oncology, Pharmacology +15
Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma
Edwin P. Hui, Vivian Wai Yan Lui, Sze Chuen Cesar Wong et al. · Investigational New Drugs · 2010 · 34 citations
Medicine, Oncology, Pharmacology +9
Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma
Chi Hang Wong, Herbert H. Loong, Connie W. C. Hui et al. · Investigational New Drugs · 2013 · 29 citations
Medicine, Oncology, Pharmacology +12
Preclinical evaluation of the mTOR–PI3K inhibitor BEZ235 in nasopharyngeal cancer models
Vivian Wai Yan Lui, Connie W. C. Hui, Cecilia P. Y. Lau et al. · Cancer Letters · 2013 · 27 citations
Medicine, Cancer Biology, Oncology +9
1–5 of 6